Chris Garabedian founded Xontogeny in June 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund, which supports early-stage companies with Series A investments across biotech, MedTech, and health tech.
Chris has a broad base of experience and a track record of success over his decades of experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial-stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Before Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Before Celgene, Chris served in several global commercial and corporate development leadership roles at Gilead from 1997 to 2005.
